Since 2007, more than 30 bio-pharmaceutical companies have been fined over $13 billion for sales and marketing compliance violations. All of these companies had compliance training programs in place to meet the 2003 OIG Compliance Program Guidance for Pharmaceutical Manufacturers. Yet, these training programs were not sufficient to prevent the violations and fines. Why? They didn’t focus enough on ensuring that training changed actual behavior in the field.